On 7 October, Nivalis Therapeutics, Inc. (NASDAQ:NVLS), announced positive topline results from a Phase 1b clinical study evaluating N91115 that demonstrated favorable safety, tolerability and pharmacokinetics in adult CF patients with two copies of the F508del-CFTR mutation. N91115 is the Company’s novel stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) belongs to Healthcare sector. Its weekly performance is -29.04%. On last trading day company shares ended up at $8.09. Nivalis Therapeutics, Inc. (NASDAQ:NVLS) distance from 50-day simple moving average (SMA50) is -46.22%.
Itau Unibanco Holding SA (NYSE:ITUB) was downgraded by equities researchers at Credit Suisse from a “neutral” rating to an “underperform” rating in a report released on Tuesday, The Fly reports.
Itau Unibanco Holding SA (ADR) (NYSE:ITUB) shares moved up 0.70% in last trading session and ended the day at $7.22. ITUB return on assets is 2.10%. Itau Unibanco Holding SA (ADR) (NYSE:ITUB) quarterly performance is -25.86%.
On 9 October, it was reported the far-reaching technology-driven transformation that Gartner, Inc. (NYSE:IT) defines as the “programmable economy” has the potential to disrupt virtually every facet of the global economy. The programmable economy represents a massive technology-enabled transformation of traditional concepts of value exchange, empowering individuals and smart machines to both define value and determine how it is exchanged.
On 14 October, Gartner Inc. (NYSE:IT) shares moved down -1.52% and was closed at $84.84. IT EPS growth in last 5 year was 19.00%. Gartner Inc. (NYSE:IT) year to date (YTD) performance is 0.75%.
Lattice Semiconductor Corporation (NASDAQ:LSCC), announced the availability of the ECP5™ Versa development kit to accelerate prototyping and testing of connectivity designs targeted for small cells, microserver, broadband access, and industrial video applications worldwide. The family’s low power consumption, small form factor and low cost make it an ideal connectivity solution and enables design engineers to rapidly add features and functions that complement those delivered by ASICs and ASSPs, reducing development risk and accelerating time-to-market.
On 7 October, Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p<0.0001), the primary endpoint of the study.